To explore the role of A2aR in the progression of CCH-induced neuroinflammation, we administered the A2aR agonist CGS21680 to CCH model rats during four distinct time periods: Days 1–7 (first week), Days 8–14 (second week), Days 15–21 (third week), and Days 22–28 (fourth week) postoperation (Fig. 2A). This evidence concerns the gene ADORA2A and columnar cell hyperplasia of the breast.